StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Thu, 15 Oct 2026 07:13:33 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ: CGTX).

The analyst commented: "Yesterday, Cognition Therapeutics announced that the United States Patent and Trademark Office (USPTO) has granted the company a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), the company’s lead drug candidate. The patent has a natural expiration of 2045. Upon zervimesine’s approval by the FDA, the patent may be eligible for an extension of up to five additional years, thus potentially prolonging exclusivity through 2050. We note that the form of zervimesine covered by this patent has

USPTO grants Cognition Therapeutics patent for zervimesine through 2045

Tue, 13 Oct 2026 06:02:24 -0400

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that the U.S. Patent and Trademark Office has granted the company a composition of matter patent covering a novel crystalline form of its lead drug candidate, zervimesine (CT1812), with a natural expiration date of 2045.

The patent, assigned U.S. Patent No. 12,759,979, covers a polymorphic crystalline form of zervimesine, a proprietary production process, and therapeutic methods for treating Alzheimer's disease, dry age-related macular degeneration, and dementia with Lewy bodies (DLB). Upon potential FDA approval, the patent may be eligible for an extension of up to five additional years.

Anthony Caggiano, M.D., Ph.D., Cognition's chief medical officer,

USPTO grants Cognition Therapeutics patent for zervimesine through 2045

Tue, 13 Oct 2026 06:02:24 -0400

Anthony Caggiano, M.D., Ph.D., Cognition's chief medical officer,

Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045

Tue, 13 Oct 2026 06:00:00 -0400

PURCHASE, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the United States Patent and Trademark Office (USPTO) has granted the company a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), the company's lead drug candidate. The patent has a natural expiration of 2045. Upon zervimesine’s approval by the U.S. Food and Drug Administration (FDA), the patent may be eligible for an extension of up to five additional years.

“The form of

Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045

Tue, 13 Oct 2026 06:00:00 -0400

“The form of

H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Mon, 05 Oct 2026 06:51:26 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ: CGTX).

The analyst commented: "Late last month, Cognition Therapeutics announced that a Type C meeting with the FDA's Division of Neurology has been scheduled for October 20, 2026. The objective of this meeting is to align with the FDA on the analytical and statistical details pertaining to the proposed primary endpoint for the planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB) who experience psychosis symptoms. Hallucinations are a core feature of DLB and often occur early in the

Cognition Therapeutics schedules FDA meeting on DLB trial endpoints

Tue, 29 Sep 2026 07:30:32 -0400

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration's Division of Neurology for Oct. 20, 2026, to discuss the analytical and statistical details of the proposed primary endpoint for a planned Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB).

The planned registrational study is expected to enroll people with DLB who experience psychosis symptoms, including hallucinations and delusions. Participants would be eligible whether on stable background medication or untreated. Following screening, participants would be randomized to receive either 100 mg of once-daily oral zervimesine or placebo

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

Tue, 29 Sep 2026 07:30:00 -0400

PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that a Type C meeting with the U.S. Food and Drug Administration (FDA) Division of Neurology has been scheduled for October 20, 2026. The objective of this meeting is to align with the FDA on the analytical and statistical details pertaining to the proposed primary endpoint for the planned registrational study of zervimesine (CT1812) in people with dementia

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

Tue, 29 Sep 2026 07:30:00 -0400

H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Thu, 13 Aug 2026 07:05:01 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ: CGTX).

The analyst commented: "Cognition Therapeutics remains slated to initiate a pivotal program with its lead candidate zervimesine to treat psychosis associated with dementia with Lewy bodies (DLB), which would support a New Drug Application (NDA). The registrational program is expected to begin in mid-2027. Cognition expects the Phase 3 study to enroll people with DLB who experience psychosis symptoms of hallucinations and delusions. Patients receiving stable background treatment with off-label antipsychotic medications shall be eligible. Following screening, participants will be randomized to receive

Form 10-Q COGNITION THERAPEUTICS For: Jun 30

Fri, 07 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26887543.html

Form 10-Q COGNITION THERAPEUTICS For: Jun 30

Fri, 07 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26887543.html

Cognition Therapeutics, Inc. (CGTX) Tops Q2 EPS by 1c

Thu, 06 Aug 2026 18:02:58 -0400

Cognition Therapeutics, Inc. (NASDAQ: CGTX) reported Q2 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05).

For earnings history and earnings-related data on Cognition Therapeutics, Inc. (CGTX) click here.

Form 8-K COGNITION THERAPEUTICS For: Aug 06

Thu, 06 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260806/26884389.html

Form 8-K COGNITION THERAPEUTICS For: Aug 06

Thu, 06 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260806/26884389.html

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

“The second quarter marked important progress across both our clinical and corporate priorities,” said Lisa Ricciardi, Cognition’s president and CEO. “Discussions with the Food and Drug Administration (FDA) brought clarity on key aspects of our planned Phase 3 trial for people with dementia with Lewy bodies (DLB) who

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit